The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
14h
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease ...
MedPage Today on MSN
Race for the Rheum Disease Cure Heats Up
For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
Sanofi (SAN:CA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM ESTCompany ParticipantsPaul Hudson - CEO & ...
CARDIO—AEROBIC ACTIVITIES like walking, running, swimming, and cycling—not only reduces total cholesterol, LDL, vLDL and ...
A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback